CStone's Novel Trispecific Antibody CS2009 Receives FDA Clearance for Phase II Trial in Advanced Solid Tumors
核心洞察
CStone Pharmaceuticals received FDA clearance for its Investigational New Drug application to advance CS2009, a novel PD-1 (搜索)/VEGF (搜索)/CTLA-4 (搜索) trispecific antibody, into Phase II clinical trials for advanced solid tumors.
The global multicenter Phase II trial features 15 cohorts evaluating monotherapy and combination regimens across 9 solid tumor indications, including non-small cell lung cancer (搜索), colorectal cancer (搜索), and triple-negative breast cancer (搜索).
Initial Phase I data presented at the 2025 ESMO meeting demonstrated a favorable safety profile with encouraging antitumor activities, with further clinical data expected at upcoming ASCO and ESMO conferences.
CStone Pharmaceuticals has achieved a significant regulatory milestone with the U.S. Food and Drug Administration clearing its Investigational New Drug application for CS2009, a novel trispecific antibody targeting PD-1 (搜索), VEGF (搜索), and CTLA-4 (搜索). The clearance enables the company to advance into Phase II clinical trials for patients with advanced solid tumors, marking a crucial step in the global development of this innovative immunotherapy.
Comprehensive Phase II Trial Design
The ongoing global multicenter Phase II trial employs a multi-cohort, parallel expansion design to evaluate the efficacy, safety, tolerability, and pharmacokinetics/pharmacodynamics of CS2009 as both monotherapy and in combination regimens. The study comprises 15 monotherapy and combination therapy cohorts across 9 solid tumor indications, including non-small cell lung cancer (搜索) (NSCLC), colorectal cancer (搜索) (CRC), triple-negative breast cancer (搜索) (TNBC), extensive-stage small cell lung cancer (搜索) (ES-SCLC), platinum-resistant ovarian cancer (搜索) (PROC), cervical cancer (搜索) (CC), hepatocellular carcinoma (搜索) (HCC), gastric or gastroesophageal junction cancer (GC/GEJC), and esophageal squamous cell carcinoma (搜索) (ESCC).
The trial is currently enrolling patients in Australia and China, with the recent FDA clearance now enabling patient enrollment in the United States.
Promising Early Clinical Data
Initial Phase I data for CS2009, previously presented at the 2025 European Society for Medical Oncology annual meeting, demonstrated a favorable safety profile with encouraging antitumor activities. The FDA's clearance followed a productive interaction with the agency, during which they reviewed comprehensive Phase I data including safety and antitumor activity data collected during dose escalation and expansion phases.
Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, stated, "We are pleased to receive FDA clearance to proceed with the global Phase II clinical trial of CS2009. This milestone follows a productive interaction with the agency, during which they reviewed our comprehensive Phase I data—including safety and antitumor activity data collected during dose escalation and expansion—and provided alignment on key elements of the Phase II study design, including dose optimization and expansion strategies."
Novel Trispecific Mechanism of Action
CS2009 represents an innovative approach to cancer immunotherapy by combining three clinically validated targets—PD-1 (搜索), VEGFA (搜索), and CTLA-4 (搜索)—to exert multidimensional anti-tumor effects through synergistic actions. The trispecific antibody's mechanism involves multiple complementary pathways: anti-PD-1 activity reverses T cell exhaustion, anti-CTLA-4 activity promotes T cell activation and proliferation, while anti-VEGFA activity blocks tumor angiogenesis and improves the tumor microenvironment.
Within the tumor microenvironment, anti-PD-1 (搜索) and anti-CTLA-4 (搜索) activities are significantly enhanced by crosslinking with VEGFA (搜索). Additionally, CS2009 preferentially blocks PD-1 and CTLA-4 on double-positive tumor-infiltrating T cells while minimizing interference with CTLA-4 regulation in peripheral T cells, potentially reducing systemic toxicity.
Company Pipeline and Development Strategy
CStone, established in late 2015, has built a robust oncology portfolio with 4 innovative drugs already launched and approvals secured for 20 new drug applications covering 9 indications. The company's pipeline includes 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates, multispecific antibodies, immunotherapies and precision medicines.
Further clinical data from both the Phase I and Phase II trials is expected to be disclosed at the upcoming American Society of Clinical Oncology and ESMO congress later this year, providing additional insights into CS2009's therapeutic potential across multiple solid tumor indications.